These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 22298228)
41. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)]. Golubchik P; Sever J; Weizman A Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124 [TBL] [Abstract][Full Text] [Related]
42. The effects of stimulant medications for ADHD. Natl Bur Econ Res Bull Aging Health; 2014; (1):1-2. PubMed ID: 25141389 [No Abstract] [Full Text] [Related]
43. [Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD]. Ludolph AG; Kölch M; Plener PL; Schulze UM; Spröber N; Fegert JM Z Kinder Jugendpsychiatr Psychother; 2009 Sep; 37(5):405-11. PubMed ID: 19739058 [TBL] [Abstract][Full Text] [Related]
44. Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. Walitza S; Melfsen S; Herhaus G; Scheuerpflug P; Warnke A; Müller T; Lange KW; Gerlach M J Neural Transm Suppl; 2007; (72):311-5. PubMed ID: 17982908 [TBL] [Abstract][Full Text] [Related]
45. ECGs before stimulants in children. Med Lett Drugs Ther; 2008 Jul; 50(1291):60. PubMed ID: 18654112 [No Abstract] [Full Text] [Related]
46. Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. DeSantis AD; Webb EM; Noar SM J Am Coll Health; 2008; 57(3):315-24. PubMed ID: 18980888 [TBL] [Abstract][Full Text] [Related]
47. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder. Findling RL; Short EJ; Manos MJ J Am Acad Child Adolesc Psychiatry; 2001 Dec; 40(12):1441-7. PubMed ID: 11765290 [TBL] [Abstract][Full Text] [Related]
48. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. Lurie S; O'Quinn A J Neuropsychiatry Clin Neurosci; 1991; 3(1):41-50. PubMed ID: 7580171 [TBL] [Abstract][Full Text] [Related]
49. Stimulant Medication Treatment in Children with Congenital Heart Disease and Attention-Deficit/Hyperactivity Disorder: Cardiovascular Outcomes. Trairatvorakul P; Meinzen-Derr J; Heydarian H; Mason K; Anixt JS J Dev Behav Pediatr; 2023 May; 44(4):e247-e254. PubMed ID: 37081695 [TBL] [Abstract][Full Text] [Related]
50. Safety of stimulant medications for attention deficit hyperactivity disorder in paediatric congenital heart disease. Chung LM; Hariharan G; Varma S J Paediatr Child Health; 2023 Mar; 59(3):580-588. PubMed ID: 36789801 [TBL] [Abstract][Full Text] [Related]
51. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. Pliszka SR; Matthews TL; Braslow KJ; Watson MA J Am Acad Child Adolesc Psychiatry; 2006 May; 45(5):520-526. PubMed ID: 16670648 [TBL] [Abstract][Full Text] [Related]
52. Attention deficit hyperactivity disorder in adults. Rösler M; Casas M; Konofal E; Buitelaar J World J Biol Psychiatry; 2010 Aug; 11(5):684-98. PubMed ID: 20521876 [TBL] [Abstract][Full Text] [Related]
53. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots. Poulin C Addiction; 2007 May; 102(5):740-51. PubMed ID: 17506151 [TBL] [Abstract][Full Text] [Related]
54. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Winterstein AG; Gerhard T; Shuster J; Saidi A Pediatrics; 2009 Jul; 124(1):e75-80. PubMed ID: 19564272 [TBL] [Abstract][Full Text] [Related]